

Call for Abstracts

The abstract submission for the HepHIV 2021 Lisbon & Virtual Conference is now open with **abstract deadline on 7 February, 2021.**

Abstract submissions are invited for the HepHIV 2021 Lisbon & Virtual Conference. The call for abstracts for HepHIV 2021 closes on 7 February 2021 and abstract decisions will be communicated to authors early April 2021.

Submit an abstract (Chrome is the preferred browser)

Aims and eligibility

HepHIV abstracts should contain original material from recent work that is not yet in publication. The HepHIV conference encourages research on testing and linkage to care as well as best practice examples and lessons learned, also in light of the COVID-19 pandemic. Also abstracts on integrated testing and linkage to care of key populations within the fields of viral hepatitis, HIV, STIs and TB are encouraged.

Abstract categories

Please see below list of topics/ tracks available for submitted abstracts for HepHIV 2021. (We encourage abstracts which focus on innovation, EE&CA and underserved populations):

- 1. Integrated testing programmes for hepatitis/HIV/TB/STI/TB
- 2. Innovative testing services during the COVID-19 pandemic; lessons learned, including community engagement in COVID-19 testing
- New testing and sampling technologies to increase testing coverage, e.g. home-based HIV testing/sampling, finger prick, oral fluid, urine etc.; obstacles overcome
- 4. Combination prevention for hepatitis/HIV/TB/STI in the COVID/post-COVID era
- 5. PrEP integration with combination prevention, including PrEP for heterosexual men, women, trans people and other underserved potential PrEP users
- 6. Models of testing and linkage to care for PWID and PWUD

- 7. Testing implementation in prisons and other closed settings
- 8. Engagement and integration of marginalised populations to develop innovative testing programmes which address multiple vulnerabilities

Tentative Programme at a Glance





PROGRAMME AT A GLANCE

Time (CET -1) Washington DC: CET -7 Sidney: CET +9			
	Wednesday, 5 May 2021		
15:00-17:00	Opening session	e: tis	
	Thursday, 6 May 2021		
09:30-11:00	Plenary session: PLE1: SPECIAL SESSION: COVID-19's impact on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building stronger systems and communities in light of lessons learned		
11:00-11:30	Break		
11:30-12:30	Parallel sessions		
	PS1: TBD	PS2: TBD	
12:30-15:00	Posters and exhibition area (break)		
15:00-16:30	Plenary session: PLE2: Combination prevention in HIV, viral hepatitis, STIs and TB		
	Friday, 7 May 2021		
09:30-11:00	Plenary session: PLE3: Implementing integrated testing strategies		
11:00-11:30	Break		
11:30-12:30	Parallel sessions		
	PS3: TBD	PS4: TBD	
12:30-14:00	Posters and exhibition area (break)		
14:00-15:30	Plenary session: PLE4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)		
15:30-16:00	Break		
16:00 -17:00	Closing session: A new health model toward an integrated continuum of care: Perspectives from different disease specific actors		

For more information about the conference check the <u>conference</u> <u>website for updates</u> or contact the HepHIV Conference Secretariat at <u>hephiv.rigshospitalet@regionh.dk</u>

